IMUNON Announces Strategic Sale of ThermoDox®GlobeNewsWire · 5 days ago
IMUNON to Participate in Upcoming Investor ConferencesGlobeNewsWire · Oct 8, 2026
IMUNON Converts $1.2 Million of Debt-to-EquityGlobeNewsWire · Sep 29, 2026
IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of PlanGlobeNewsWire · Sep 24, 2026
Imunon, Inc. (IMNN) Shareholder/Analyst Call TranscriptSeeking Alpha · Sep 23, 2026
IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety ReviewGlobeNewsWire · Sep 22, 2026Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$0.87 | -$0.54 | Beat |
| May 12, 2026 | -$1.22 | -$0.84 | Beat |
| Mar 31, 2026 | -$1.43 | -$1.29 | Beat |
| Nov 13, 2025 | -$1.20 | -$1.16 | Beat |
| Aug 5, 2025 | -$3.09 | -$1.87 | Beat |
| May 12, 2025 | -$4.56 | -$3.65 | Beat |